Search

Your search keyword '"Nam, Eun Ji"' showing total 17 results
Start Over Author "Nam, Eun Ji" Journal journal of gynecologic oncology
17 results on '"Nam, Eun Ji"'

1. Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

Author

Yoo, Ji Geun, primary, Lee, Sung Jong, additional, Nam, Eun Ji, additional, No, Jae Hong, additional, Park, Jeong Yeol, additional, Song, Jae Yun, additional, Shin, So-Jin, additional, Yun, Bo Seong, additional, Park, Sung Taek, additional, Lee, San-Hui, additional, Suh, Dong Hoon, additional, Kim, Yong Beom, additional, Lee, Taek Sang, additional, Bae, Jae Man, additional, and Lee, Keun Ho, additional

Published
2024
Full Text
View/download PDF

2. Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

Author

Lim, Myong Cheol, Lee, Maria, Shim, Seung Hyuk, Nam, Eun Ji, Lee, Jung Yun, Kim, Hyun Jung, Lee, Yoo-Young, Lee, Kwang Beom, Park, Jeong Yeol, Kim, Yun Hwan, Do Ki, Kyung, Song, Yong Jung, Chung, Hyun Hoon, Kim, Sunghoon, Lee, Jeong-won, Kim, Jae-Weon, Bae, Duk-Soo, and Lee, Jong-Min

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Cancer, Cervical Cancer, Adenosarcoma, Consensus, Female, Humans, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Republic of Korea, Societies, Medical, Uterine Cervical Neoplasms, Practice Guideline, General Surgery, Chemotherapy, Irradiation, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology and carcinogenesis, Reproductive medicine
Abstract

Clinical practice guidelines for gynecologic cancers have been developed by academic society from several countries. Each guideline reflected their own insurance system and unique medical environment, based on the published evidence. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to develop the third edition of the guidelines in an advanced format based on evidence-based medicine, embracing up-to-date clinical trials and qualified Korean data. These guidelines cover strategies for diagnosis and treatment of primary and recurrent cervical cancer. The committee members and many gynecologic oncologists derived key questions through discussions, and a number of relevant scientific literature were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the management in cervical cancer based on the results in published papers to date and the consensus of experts as a KSGO Consensus Statement.

Published
2017

9. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma

Author

Lee, Jung-Yun, primary, Chung, Young Shin, additional, Na, Kiyong, additional, Kim, Hye Min, additional, Park, Cheol Keun, additional, Nam, Eun Ji, additional, Kim, Sunghoon, additional, Kim, Sang Wun, additional, Kim, Young Tae, additional, and Kim, Hyun-Soo, additional

Published
2017
Full Text
View/download PDF

16. Expression of the p16INK4a and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection

Author

Nam, Eun Ji, primary, Kim, Jae Wook, additional, Hong, Jong Wook, additional, Jang, Hyoung Sun, additional, Lee, Sang Yub, additional, Jang, Si Young, additional, Lee, Dae Woo, additional, Kim, Sang Wun, additional, Kim, Jae Hoon, additional, Kim, Young Tae, additional, Kim, Sunghoon, additional, and Kim, Jong Wook, additional

Published
2008
Full Text
View/download PDF

17. The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.

Author

Lee YJ, Kim W, Hong S, Lee YJ, Lee JY, Kim SW, Kim S, Kim YT, and Nam EJ

Abstract

Objective: To investigate the efficacy of cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) in predicting survival outcomes based on breast cancer gene (BRCA) mutational status in epithelial ovarian cancer., Methods: Medical records of 448 patients diagnosed with epithelial ovarian cancer at a single tertiary institution in Korea were retrospectively analyzed. Area under the curve, sensitivity, specificity, and accuracy were assessed using the CA125 and HE4 values after surgery and 3 cycles of chemotherapy to predict 1-year survival based on the BRCA mutational status. Kaplan-Meier analysis was used to obtain progression-free and overall survival to evaluate CA125 and HE4 effectiveness in predicting survival outcomes., Results: A total of 423 patients were analyzed, including 180 (42.6%) who underwent interval debulking surgery (IDS) and 243 (57.4%) who underwent primary debulking surgery (PDS). BRCA mutations were observed in 37 (15.2%) and 44 (22.4%) patients in the PDS and IDS groups, respectively. CA125 and HE4 normalization demonstrated the highest specificity in patients with or without BRCA mutations, with specificities of 97.1% and 99.1% in the PDS group and 78.6% and 86.2% in the IDS group, respectively. Normalizing HE4 alone may be an effective prognostic marker, with an area under the curve of 0.774 and specificity of 75.0%, in patients with BRCA mutations., Conclusion: Normalizing both biomarkers emerged as the most effective predictive marker for the 1-year recurrence rate, regardless of BRCA mutational status. A negative HE4 value can be a useful predictor for 1-year recurrence-free survival in patients with BRCA mutations., Competing Interests: No potential conflict of interest relevant to this article was reported., (© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results